Nat Med Aug;15(8):871-2.

Size: px
Start display at page:

Download "Nat Med. 2009 Aug;15(8):871-2."

Transcription

1 1. Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; the ANRS AC11 Resistance study group. Antimicrob Agents Chemother Nov High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Clin Infect Dis Nov 1;49(9): Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after longterm suppressive antiretroviral therapy in 236 patients. Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C; ANRS AC11 Working Group. AIDS Oct 23;23(16): Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group. J Antimicrob Chemother Jul;64(1): Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S; ANRS CO5 HIV-2 Cohort Study Group. AIDS Jun 1;23(9): Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drugexperienced patients besides compensating for fitness loss. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F; ANRS 109 Study Group. PLoS Pathog Mar;5(3):e The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun- Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. J Virol May;83(10): Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother Mar;63(3): A new human immunodeficiency virus derived from gorillas. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F.

2 Nat Med Aug;15(8): Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. AIDS Jan 28;23(3): Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; on behalf of the Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. AIDS Oct Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group. J Antimicrob Chemother Sep;64(3): Predictive value of HIV-1 genotypic resistance test interpretation algorithms. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. J Infect Dis Aug 1;200(3): Uncontrolled viral replication as a risk factor for non-aids severe clinical events in HIVinfected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chêne G, Leport C, Moing VL; ANRS CO8 (APROCO-COPILOTE) Study Group. J Acquir Immune Defic Syndr Aug 1;51(4): Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F; COPHAR2-ANRS 111 Study Group. Eur J Clin Pharmacol Jul;65(7): Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE study group. AIDS May 15;23(8): Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Gut Jan;58(1): Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

3 Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F. Antivir Ther. 2009;14(6): , Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Leport C, Duval X; IMAGE Study Group. Stroke Nov;40(11): Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. AIDS Nov 13;23(17): Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B. Antivir Ther. 2009;14(5): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis Sep 15;200(6): Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S; FHDH-ANRS CO4 Clinical Epidemiology Group. AIDS Sep 24;23(15): Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X. Dis Colon Rectum Jun;52(6): Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over in France. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. AIDS Mar 27;23(6): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

4 Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Clin Infect Dis Mar 1;48(5): Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. HIV Med Feb;10(2): How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'etude Mortalité HIV Med Apr;10(4): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS Jan 2;23(1): Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D. AIDS Oct Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.

5 Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S. Eur J Obstet Gynecol Reprod Biol Dec;147(2): Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient. Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F. J Clin Microbiol Nov;47(11): Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group. Antivir Ther. 2009;14(1):75-83 Peytavin G. 39 Clinical pharmacokinetic of maraviroc] Med Mal Infect Mar;38 Suppl 1:S High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM. J Antimicrob Chemother Feb;63(2): Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Tréluyer JM; ANRS Clin Pharmacol Ther Feb;85(2): Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, Schneider V, Burgard M, Faye A, Mandelbrot L, Tubiana R, Rouzioux C; ANRS French Perinatal Cohort. Retrovirology Sep 19;6:85.

6 43 No relation between in-utero exposure to HAART and intrauterine growth retardation. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort. AIDS Jun 19;23(10): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R, Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (EPF). Am J Obstet Gynecol Feb;200(2):160.e Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients. Landman R, Poupard M, Diallo M, Gueye NF, Diakhate N, Ndiaye B, Kane CT, Trylesinski A, Diop H, Mboup S, Fall MB, Deleporte E, Benalycherif AD, Girard PM, Sow PS. J Int Assoc Physicians AIDS Care (Chic Ill) Sep Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire. Spire B, Arnould B, Barbier F, Durant J, Gilquin J, Landman R, Carret S, Saussier C, El Kebir S, Cohen-Codar I. HIV Clin Trials Jul-Aug;10(4): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

7 J Infect Dis Sep 15;200(6): HIV genetic diversity and its consequences.] Roquebert B, Damond F, Brun-Vézinet F, Descamps D. Pathol Biol (Paris) Mar;57(2):142-8.

1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION *

1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION * 1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION * Our simulation separately tracks the number of accumulated genetic mutations that may confer resistance to each of the three main drug categories

More information

HIV Drug resistanceimplications

HIV Drug resistanceimplications HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania

Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania Antiviral Therapy 13 Suppl 2:77 82 Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania Geofrey R Somi 1, Tabitha Kibuka 2, Karidja Diallo

More information

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Antiretroviral therapy for HIV infection in infants and children: Towards universal access Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous

More information

Reference: NHS England B06/P/a

Reference: NHS England B06/P/a Clinical Commissioning Policy: Dolutegravir for treatment of HIV- 1 in adults and adolescents Reference: NHS England B06/P/a 1 NHS England Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1

More information

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Positive impact of HCV treatment initiation on health outcomes in injecting drug users Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction

More information

Routine HIV Monitoring

Routine HIV Monitoring Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral

More information

A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping

A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping Cynthia J. Carlyn, MD * Aldona L. Baltch, MD * Marty H. St. Clair, BS Mary J. George, PhD * Raymond P. Smith,

More information

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial) Short communication Antiviral Therapy 12:417 422 Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial) Jean-Michel Molina 1 *, Valérie Journot

More information

!400 copies/ml [12, 13]. Continuous viral suppression

!400 copies/ml [12, 13]. Continuous viral suppression HIV/AIDS MAJOR ARTICLE Virological Control during the First 6 18 Months after Initiating Highly Active Antiretroviral Therapy as a Predictor for Outcome in HIV-Infected Patients: A Danish, Population-Based,

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

Antiretroviral Drugs in the Treatment and Prevention of HIV Infection

Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

Testing for HIV Drug Resistance

Testing for HIV Drug Resistance State of the Art Testing for HIV Drug Resistance Victor S.B. Jorden, MD, MPH Sindy M. Paul, MD, MPH Today, many patients with HIV infection are able to live longer and better lives, owing to the use of

More information

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network

More information

Chapter 10 Human Immuno Deficiency Virus Infection

Chapter 10 Human Immuno Deficiency Virus Infection 143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended

More information

Réservoirs VIH : du contrôle à l'éradication. Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales

Réservoirs VIH : du contrôle à l'éradication. Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Réservoirs VIH : du contrôle à l'éradication Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales M. Coiras et al Nat Rev Micro 2009 HIV-1 life cycle and latency HIV-1 life cycle and

More information

HIV Genotyping and Phenotyping

HIV Genotyping and Phenotyping Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA

Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA D Armenia 1, M Zaccarelli 2, V Borghi 3, W Gennari 3, A Giannetti

More information

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data). HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and

More information

VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral.

VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral. VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral. Juan Carlos Salazar, M.D. Universidad de Connecticut, EE.UU. End-1998 global estimates Children (

More information

HBV screening and management in HIV-infected children and adolescents

HBV screening and management in HIV-infected children and adolescents HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally

More information

Aktuell HIV-forskning 2014-05-06

Aktuell HIV-forskning 2014-05-06 Aktuell HIV-forskning 2014-05-06 Alexey Kashpersky Aktuell HIV-forskning Bot Smittsamhet Nya läkemedel HIV och åldrande Etc HPTN 052 Prevention Conclusion Early ART that suppresses viral replication led

More information

The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing firstline treatment regimen selection

The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing firstline treatment regimen selection DOI: 10.1111/j.1468-1293.2008.00561.x r 2008 Merck & Co., Inc. HIV Medicine (2008), 9, 285 293 ORIGINAL RESEARCH The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients

More information

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors.

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. Delphine Desbois, Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin,

More information

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

More information

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression M42-Determinants M19 of HIV Sustained Viral Suppression in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression F. Bani-Sadr 1-2, M-A Loko 2, E. Pambrun 2, M. Winnock 2, P. Carrieri

More information

Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries

Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries 1. Authors James H. McMahon Alfred Hospital, Melbourne, Australia

More information

HIV Guidelines. New Strategies.

HIV Guidelines. New Strategies. HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

La sospensione dell ARV è sempre una cattiva idea?

La sospensione dell ARV è sempre una cattiva idea? 15/05/2014 La sospensione dell ARV è sempre una cattiva idea? Adriano Lazzarin IRCCS Ospedale San Raffaele, Università Vita e Salute, Milano 6 Infectivology Today I due principi che guideranno il management

More information

Paediatric HIV Drug Resistance in African Settings

Paediatric HIV Drug Resistance in African Settings Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV

More information

British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010

British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010 DOI: 10.1111/j.1468-1293.2010.00889.x r 2010 British HIV Association HIV Medicine (2010), 11, 611 619 BRITISH HIV ASSOCIATION GUIDELINES British HIV Association guidelines for antiretroviral treatment

More information

Predicting the unpredictable: Transmission of drug-resistant HIV

Predicting the unpredictable: Transmission of drug-resistant HIV Predicting the unpredictable: Transmission of drug-resistant HIV S.M. BLOWER 1, A.N. ASCHENBACH 1, H.B. GERSHENGORN 2 & J.O. KAHN 3 1 Department of Biomathematics and UCLA AIDS Institute, UCLA School of

More information

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session. Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS

More information

Perspective Incomplete Viral Suppression Under Potent Antiretroviral Therapy: Determinants of Treatment Outcome

Perspective Incomplete Viral Suppression Under Potent Antiretroviral Therapy: Determinants of Treatment Outcome Perspective Incomplete Viral Suppression Under Potent Antiretroviral Therapy: Determinants of Treatment Outcome At the International AIDS Society USA course in Los Angeles in March 22, Steven G. Deeks,

More information

Initiating Therapy: When to Start, What to Use

Initiating Therapy: When to Start, What to Use SUPPLEMENT ARTICLE Initiating Therapy: When to Start, What to Use Martin S. Hirsch Massachusetts General Hospital, Harvard Medical School, Boston Decisions regarding whether to start combination antiretroviral

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

Treating HIV in children with tuberculosis

Treating HIV in children with tuberculosis International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges

More information

CLINICAL REVIEW. HIV infection, antiretroviral treatment, ageing, and non-aids related morbidity. Steven G Deeks, 1 Andrew N Phillips 2

CLINICAL REVIEW. HIV infection, antiretroviral treatment, ageing, and non-aids related morbidity. Steven G Deeks, 1 Andrew N Phillips 2 For the full versions of these articles see bmj.com HIV infection, antiretroviral treatment, ageing, and non-aids related morbidity Steven G Deeks, 1 Andrew N Phillips 2 1 Positive Health Program, San

More information

Register for e-mail notification of guideline updates at http://aidsinfo.nih.gov/e-news.

Register for e-mail notification of guideline updates at http://aidsinfo.nih.gov/e-news. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website

More information

Routine testing to reduce late HIV diagnosis in France.

Routine testing to reduce late HIV diagnosis in France. Routine testing to reduce late HIV diagnosis in France. Cyrille Delpierre, Lise Cuzin, France Lert To cite this version: Cyrille Delpierre, Lise Cuzin, France Lert. Routine testing to reduce late HIV diagnosis

More information

Issues in Perinatally HIV Infected Adolescents. Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston

Issues in Perinatally HIV Infected Adolescents. Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston Issues in Perinatally HIV Infected Adolescents Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston Perinatally HIV Infected Adolescents Who are they? How many? Issues of special impact MTCT Race

More information

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What

More information

HIV and Hepatitis B CoInfection

HIV and Hepatitis B CoInfection HIV and Hepatitis B CoInfection Douglas G. Fish, MD June 3, 2014 44 yo male with AIDS who had fallen out of care and returned in October 2013 Last seen in November 2012 CD4 at that time 340 cells/cmm HIV

More information

The treatment of HIV is currently focused on drug

The treatment of HIV is currently focused on drug Vol 1 October 2009 Clinical Pharmacist 393 Since the advent of combination antiretroviral therapy in the mid-1990s HIV-infected individuals are now living longer with improved quality of life. Medication

More information

Highly active antiretroviral therapy and survival in HIV-infected Injection drug users: implications for the critical role of adherence

Highly active antiretroviral therapy and survival in HIV-infected Injection drug users: implications for the critical role of adherence Highly active antiretroviral therapy and survival in HIV-infected Injection drug users: implications for the critical role of adherence Robert Hogg, PhD BC Centre for Excellence in HIV/AIDS and Simon Fraser

More information

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007

More information

Analysis One Code Desc. Transaction Amount. Fiscal Period

Analysis One Code Desc. Transaction Amount. Fiscal Period Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

Janssen Global Public Health: HIV Medicines Access & Partnerships Program APRIL 2014. Julius Bustamante, Pajaros

Janssen Global Public Health: HIV Medicines Access & Partnerships Program APRIL 2014. Julius Bustamante, Pajaros Julius Bustamante, Pajaros Artwork from Hospital Audiences, Inc. (HAI), a nonprofit organization that inspires healing, growth and learning through access to the arts for the culturally underserved. Janssen

More information

POSTEXPOSURE PROPHYLAXIS

POSTEXPOSURE PROPHYLAXIS POSTEXPOSURE PROPHYLAXIS Bloodborne viruses Hepatitis B Hepatitis C HIV Hepatitis B Risk of seroconversion HBeAg negative 2% HBeAg positive 20-40% If seroconvert most recover completely and develop immunity

More information

Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy

Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy Perspective Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy Antiretroviral therapy is recommended for all patients with

More information

Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults

Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Reference: NHS England B06/P/x 1 Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults

More information

Liver Disease and Therapy of Hepatitis B Virus Infections

Liver Disease and Therapy of Hepatitis B Virus Infections Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin

More information

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH

More information

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen

More information

Optimal drug treatment regimens for HIV depend on adherence

Optimal drug treatment regimens for HIV depend on adherence Journal of Theoretical Biology 246 (27) 499 59 www.elsevier.com/locate/yjtbi Optimal drug treatment regimens for HIV depend on adherence O. Krakovska, L.M. Wahl Department of Applied Mathematics, University

More information

HIV Reports. Antiretroviral Stewardship in a Pediatric HIV Clinic. Development, Implementation and Improved Clinical Outcomes

HIV Reports. Antiretroviral Stewardship in a Pediatric HIV Clinic. Development, Implementation and Improved Clinical Outcomes HIV Reports Antiretroviral Stewardship in a Pediatric HIV Clinic Development, Implementation and Improved Clinical Outcomes Alice J. Hsu, PharmD, BCPS, AQ-ID,* Asha Neptune, MA, MPH, Constants Adams, BS,

More information

Viral load testing. medical monitoring: viral load testing: 1

Viral load testing. medical monitoring: viral load testing: 1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the

More information

Chapter 3 South African guidelines and introduction to clinical cases

Chapter 3 South African guidelines and introduction to clinical cases Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Articles. Funding Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.

Articles. Funding Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, Jacques Cadranel,

More information

Die Toronto Konferenz. K. Arasteh Auguste-Viktoria-Klinikum

Die Toronto Konferenz. K. Arasteh Auguste-Viktoria-Klinikum Die Toronto Konferenz K. Arasteh Auguste-Viktoria-Klinikum Subjektive Schwerpunkte Medizinische Prävention Monotherapie CD4 guided treatment interuption (CD4-TI) HIV Prävention (Gita Ramjee) Rationale

More information

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of

More information

HIV/AIDS: Controversies 2008-10

HIV/AIDS: Controversies 2008-10 HIV/AIDS: Controversies 2008-10 1. Prevention 2. Treatment Josep M Gatell Hospital Clinic. Barcelona. gatell0@attglobal.net AIDS: year 2008-10 AIDS is a STD and a world wide epidemy (sub-saharan Africa,

More information

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:

More information

Authors: Matthew Fox *, Prudence Ive, Lawrence Long, Mhairi Maskew, Ian Sanne

Authors: Matthew Fox *, Prudence Ive, Lawrence Long, Mhairi Maskew, Ian Sanne Successful Second Line Antiretroviral Therapy with High Rates of Survival, Immune Reconstitution and Virologic suppression in a Large Urban Clinic in Johannesburg, South Africa Authors: Matthew Fox *,

More information

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT What is the purpose of this report? The purpose of this report is to present the administrative policies and clinical guidelines for the

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Chapter 21. What Are HIV and AIDS?

Chapter 21. What Are HIV and AIDS? Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome

More information

Key Components of HIV Medical Case Management:

Key Components of HIV Medical Case Management: Key Components of HIV Medical Case Management: Treatment Adherence Prevention with Positives Updated 11/28/12 1 Treatment Adherence Counseling Every goal on the care plan must relate to HIV treatment/care.

More information

With the use of combination antiretroviral therapy (ART),

With the use of combination antiretroviral therapy (ART), CLINICAL SCIENCE in an Urban HIV Clinic Gregory K. Robbins, MD, MPH,* Brock Daniels, MPH,* Hui Zheng, PhD, Henry Chueh, MD, James B. Meigs, MD, MPH, and Kenneth A. Freedberg, MD, MSc* Background: Predictors

More information

Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort.

Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. TUPE089 Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. Authors: Adedotun A. Adetunji 1, MBChB, MSc; Chad Achenbach 2, MD, MPH; Joseph Feinglass 3, PhD; Kristin

More information

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017 From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days

More information

EACS 2013. Dominique Braun Universitätsspital Zürich

EACS 2013. Dominique Braun Universitätsspital Zürich EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir

More information

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of

More information

Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma

Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma MAJOR ARTICLE Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma Alexander Zoufaly, 1 Hans-Jürgen Stellbrink, 2 Matthias an der Heiden, 3

More information

Exposure. What Healthcare Personnel Need to Know

Exposure. What Healthcare Personnel Need to Know Information from the Centers for Disease Control and Prevention National Center for Infectious Diseases Divison of Healthcare Quality Promotion and Division of Viral Hepatitis For additional brochures

More information

Guidance for Industry Role of HIV Resistance Testing in Antiretroviral Drug Development

Guidance for Industry Role of HIV Resistance Testing in Antiretroviral Drug Development Guidance for Industry Role of HIV Resistance Testing in Antiretroviral Drug Development U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry

Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Southern African HIV Clinicians Society Clinical Guidelines Antiretroviral therapy in adults

Southern African HIV Clinicians Society Clinical Guidelines Antiretroviral therapy in adults Southern African HIV Clinicians Society Clinical Guidelines Antiretroviral therapy in adults Introduction The magnitude of HIV infection in Southern African and the number of impoverished people who desperately

More information

Xavière Panhard and France Mentré. INSERM U738 - CHU Bichat Claude Bernard. Xavière Panhard - INSERM U738-16/06/05 p. 1

Xavière Panhard and France Mentré. INSERM U738 - CHU Bichat Claude Bernard. Xavière Panhard - INSERM U738-16/06/05 p. 1 Non-linear mixed-effects models for tests of interaction or of lack of interaction in cross-over and parallel pharmacokinetic studies: application to the test of interaction between protease inhibitors

More information

The value of urine protein/creatinine (upcr) and albumin/creatinine ratios (uacr) in assessing renal disease in HIV infection

The value of urine protein/creatinine (upcr) and albumin/creatinine ratios (uacr) in assessing renal disease in HIV infection The value of urine protein/creatinine (upcr) and albumin/creatinine ratios (uacr) in assessing renal disease in HIV infection A Samarawickrama, S Holt, K Nambiar, M Fisher, Y Gilleece Brighton and Sussex

More information

CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTH CARE AND SUPPORT SERVICES HIV MEDICATION ADHERENCE PROGRAM PROTOCOL

CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTH CARE AND SUPPORT SERVICES HIV MEDICATION ADHERENCE PROGRAM PROTOCOL CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTH CARE AND SUPPORT SERVICES HIV MEDICATION ADHERENCE PROGRAM PROTOCOL Revised July 2013 HIV MEDICATION ADHERENCE PROGRAM PROGRAM OVERVIEW People living with

More information

SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV

SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEY REPORT AIDS & TB UNIT Ministry Of Health And Child Welfare Zimbabwe December 2012 1 Table

More information

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department

More information

Amin Khademi 1, R. Scott Braithwaite 2,3, Denis Saure 4, Andrew J. Schaefer 5, Kimberly Nucifora 3, Mark S. Roberts 5,6,7 * Abstract

Amin Khademi 1, R. Scott Braithwaite 2,3, Denis Saure 4, Andrew J. Schaefer 5, Kimberly Nucifora 3, Mark S. Roberts 5,6,7 * Abstract Should Expectations about the Rate of New Antiretroviral Drug Development Impact the Timing of HIV Treatment Initiation and Expectations about Treatment Benefits? Amin Khademi 1, R. Scott Braithwaite 2,3,

More information

APPENDIX C: Viral Load Suppression Measures

APPENDIX C: Viral Load Suppression Measures Newark EMA HIV Health Services Planning Council Needs Assessment 2012 Update APPENDIX C: Viral Load Suppression Measures Page C-1 APPENDIX C: Viral Load Suppression Measures in+care Campaign Measures November

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information